Abstract Library

#4131 Peptide receptor radionuclide therapy (PRRT) in patients with neuroendocrine neoplasms: A prospective multi-site study evaluating quality of life and objective response

Introduction: Neuroendocrine neoplasms (NENs) are associated with poor health-related quality of life (HRQOL) due to tumor and hormonal related symptoms and treatment-related toxicity. Peptide receptor radionuclide therapy (PRRT) delivers targeted therapy for tumor and hormonal control.

Conference:

Presenting Author: Cehic G

Authors: Cehic G, Kong G, Corsini N, Chan D, Pavlakis N,

Keywords: PRRT, NENs, HRQOL,

#3988 Management and surveillance for rectal neuroendocrine tumors: A single-centre retrospective analysis and comparison with ENETS guidelines

Introduction: Rectal neuroendocrine tumors (rNETs) are rare but are increasing in incidence. Current management and surveillance recommendations are primarily based on low-grade evidence.

Conference:

Presenting Author:

Authors: Barnard P,

Keywords: rectal neuroendocrine tumor, R1 resection, ENETS guideliens,

#3698 PRRT for control of hypoglycaemia and disease progression due to metastatic insulinoma

Introduction: Management of metastatic insulinoma (MI) presents dual management challenges of hypoglycaemia (hypo) and progressive oncologic disease. Case reports describe remarkable responses to PRRT but limited follow-up (FU).

Conference:

Presenting Author: Pattison D

Authors: Pattison D, Kong G, Hofman M, Akhurst T, Ravi Kumar A,

Keywords: Insulinoma, PRRT, hypoglycaemia, [177Lu]Lu-DOTATATE,

#3648 Treatment preferences for somatostatin analogues in neuroendocrine tumors (NETs) among patients, clinicians and nurses in Australia

Introduction: Long-acting somatostatin analogues (LA SSAs) are commonly used as first-line treatment in low-grade pancreatic or midgut neuroendocrine tumors (NETs). Due to the long-term nature of treatment, treatment preferences should be taken into consideration. Funding for this study was provided by Ipsen.

Conference:

Presenting Author:

Authors: Cummins M, Fifer S, Winkler K, Cherian H,

Keywords: Treatment preferences, LA SSAs, NET,

#3578 Optimal PLAnning of treatment and research of Neuroendocrine Tumors (NETs) in Australia: The PLANET registry and patient reported outcomes via PLANET App

Introduction: Neuroendocrine Neoplasms (NENs) are challenging to diagnose and manage due to their varied behaviour. Despite usually having an indolent course, they are often metastatic at diagnosis and can be associated with significant long-term morbidity and impaired quality-of-life (QOL). The PLANET registry was established to collate clinical data from tertiary NET centres and integrate these with real-time patient reported outcomes (PROs) enabled by the smartphone-based PLANET App.

Conference:

Presenting Author: Leyden S

Authors: Leyden S, Cummins M, Pavlakis N, Ransom D, Price T,

Keywords: data, PROMS, PROs, QOLs, real-world data,